Depression In a pooled analysis of 7 comparative trials with imipramine,<unk>  and imipramine were shown to have comparable efficacy while<unk>  was significantly better tolerated. A pooled analysis of studies comparing<unk>  and SSRIs concluded a superior efficacy for<unk>  with similar tolerability for<unk>  and SSRIs. A more recent meta-analysis of 6 studies involving more than 1,000 patients showed no distinction between<unk>  and SSRIs in efficacy or discontinuation rates, including discontinuation for side effects or lack of efficacy. A meta-analysis of a total of 16 randomized controlled trials with more than 2200 patients concluded that there were no statistically significant differences in efficacy, acceptability and tolerability when comparing<unk>  with other antidepressant agents. However, compared with TCAs, significantly fewer patients taking<unk>  dropped out due to adverse events. As with other antidepressants, 1 to 3 weeks may elapse before significant antidepressant action becomes clinically evident. Fibromyalgia During its development for fibromyalgia,<unk>  was evaluated utilizing a composite responder approach. To be considered as a responder for the composite ‘treatment of fibromyalgia’ endpoint, each patient had to show concurrent and clinically meaningful improvements in pain, physical function, and global impression of disease status. A systematic review in 2015 showed moderate relief for a minority of people with fibromyalgia.<unk>  was associated with increased adverse events when discontinuing use of the drug. Social anxiety There is some evidence that<unk>  may be effective for social anxiety.
Milnacipran
Levomilnacipran
Tezacaftor
Damoctocog alfa pegol
Glysobuzole
Amivantamab
Naloxegol
Glybuzole